Fulcrum Therapeutics, INC. 8-K Filing

Ticker: FULC · Form: 8-K · Filed: Aug 28, 2025 · CIK: 1680581

Fulcrum Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyFulcrum Therapeutics, INC. (FULC)
Form Type8-K
Filed DateAug 28, 2025
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Fulcrum Therapeutics, INC. (ticker: FULC) to the SEC on Aug 28, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common stock, par value $0.001 per share FULC Nasdaq Global Market).

How long is this filing?

Fulcrum Therapeutics, INC.'s 8-K filing is 2 pages with approximately 526 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-08-28 10:41:12

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 28, 2025, Fulcrum Therapeutics, Inc., or Fulcrum, made available an updated corporate presentation that may be used in connection with presentations at conferences and investor meetings, which can be found in the "Events and Presentations" section on the Company's website. The corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1+ Corporate Presentation Dated August 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) + Furnished herewith.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FULCRUM THERAPEUTICS, INC. Date: August 28, 2025 By: /s/ Alex C. Sapir Name: Alex C. Sapir Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing